GRACEcast Social Work and Coping Audio podcast

Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

0:00
7:28
Retroceder 15 segundos
Avanzar 15 segundos

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.

Otros episodios de "GRACEcast Social Work and Coping Audio"